Cochrane · systematic review · CD013484
Tocilizumab for giant cell arteritis
Antonio, AA, Santos, RN, Abariga, SA · Cochrane Database of Systematic Reviews · 2022 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
50
current version
GRADE rated
34
No studies
16
Included studies
NR
No studies 16 · 32%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 34 · 68%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Show all 2 versionsTocilizumab every 4 weeks compared to placebo for giant cell arteritis
Population: adults aged over 50 years with giant cell arteritis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Proportion of participants with sustained remission (as defined by study investigators) at ≥ 12 months Tocilizumab every 4 weeks vs placebo | RR 4.25 [1.21, 14.88] | 1 study · 30 participants | Moderate Downgraded: imprecision |
Proportion of participants with relapse‐free survival at ≥ 12 months Tocilizumab every 4 weeks vs placebo | RR 4.25 [1.21, 14.88] | 1 study · 30 participants | Moderate Downgraded: imprecision |
Proportion of all‐cause mortality at ≥ 12 months Tocilizumab every 4 weeks vs placebo | RR 0.17 [0.01, 3.94] | 1 study · 30 participants | Moderate Downgraded: imprecision |
Mean time to first relapse after induction of remission (weeks) at ≥ 12 months Tocilizumab every 4 weeks vs placebo | MD 25 [11.4, 38.6] | 1 study · 30 participants | Moderate Downgraded: imprecision |
Cumulative mean dose of corticosteroids at ≥ 12 months Tocilizumab every 4 weeks vs placebo | no estimate extracted | 1 study · 30 participants | Moderate Downgraded: imprecision |
Proportion of participants who did not need escape therapy (as defined by study investigators) Tocilizumab every 4 weeks vs placebo | no estimate extracted | NR | No studies |
Mean change in quality of life at ≥ 12 months using the 36‐Item Short Form Health Survey physical component score (SF‐36 PCS) Tocilizumab every 4 weeks vs placebo | no estimate extracted | NR | No studies |
Mean change in quality of life at ≥ 12 months using the 36‐Item Short Form Health Survey mental component score (SF‐36 MCS) Tocilizumab every 4 weeks vs placebo | no estimate extracted | NR | No studies |
Mean change in VAS (higher scores suggest greater disease activity and worse quality of life) at ≥ 12 months Tocilizumab every 4 weeks vs placebo | no estimate extracted | NR | No studies |
Adverse events at ≥ 12 months Tocilizumab every 4 weeks vs placebo | RR 1.07 [0.66, 1.73] | 1 study · 30 participants | Moderate Downgraded: imprecision |
Tocilizumab weekly compared to placebo + 52‐week taper for giant cell arteritis
Population: adults aged over 50 years with giant cell arteritis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Proportion of participants with sustained remission (as defined by study investigators) at ≥ 12 months Tocilizumab weekly vs placebo + 52‐week taper | RR 3.17 [1.71, 5.89] | 1 study · 151 participants | Moderate Downgraded: imprecision |
Proportion of participants with relapse‐free survival at ≥ 12 months Tocilizumab weekly vs placebo + 52‐week taper | RR 1.51 [1.13, 2.02] | 1 study · 151 participants | Moderate Downgraded: imprecision |
Proportion of all‐cause mortality at ≥ 12 months Tocilizumab weekly vs placebo + 52‐week taper | no estimate extracted | NR | No studies |
Mean time to first relapse after induction of remission (weeks) at ≥ 12 months Tocilizumab weekly vs placebo + 52‐week taper | no estimate extracted | NR | No studies |
Cumulative mean dose of corticosteroids at ≥ 12 months Tocilizumab weekly vs placebo + 52‐week taper | no estimate extracted | NR | No studies |
Proportion of participants who did not need escape therapy (as defined by study investigators) Tocilizumab weekly vs placebo + 52‐week taper | RR 1.71 [1.24, 2.35] | 1 study · 151 participants | Moderate Downgraded: imprecision |
Mean change in quality of life at ≥ 12 months using the 36‐Item Short Form Health Survey physical component score (SF‐36 PCS) Tocilizumab weekly vs placebo + 52‐week taper | MD 8.18 [4.44, 11.9] | 1 study · 77 participants | Moderate Downgraded: imprecision |
Mean change in quality of life at ≥ 12 months using the 36‐Item Short Form Health Survey mental component score (SF‐36 MCS) Tocilizumab weekly vs placebo + 52‐week taper | MD 5.61 [0.06, 11.16] | 1 study · 77 participants | Moderate Downgraded: imprecision |
Mean change in VAS (higher scores suggest greater disease activity and worse quality of life) at ≥ 12 months Tocilizumab weekly vs placebo + 52‐week taper | no estimate extracted | 1 study · 78 participants | Moderate Downgraded: imprecision |
Adverse events at ≥ 12 months Tocilizumab weekly vs placebo + 52‐week taper | RR 1.06 [0.98, 1.16] | 1 study · 151 participants | Moderate Downgraded: imprecision |
Tocilizumab weekly compared to placebo + 26‐week taper for giant cell arteritis
Population: adults aged over 50 years with giant cell arteritis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Proportion of participants with sustained remission (as defined by study investigators) at ≥ 12 months Tocilizumab weekly vs placebo + 26‐week taper | RR 4 [1.97, 8.12] | 1 study · 150 participants | Moderate Downgraded: imprecision |
Proportion of participants with relapse‐free survival at ≥ 12 months Tocilizumab weekly vs placebo + 26‐week taper | RR 2.41 [1.58, 3.65] | 1 study · 150 participants | Moderate Downgraded: imprecision |
Proportion of all‐cause mortality at ≥ 12 months Tocilizumab weekly vs placebo + 26‐week taper | no estimate extracted | NR | No studies |
Mean time to first relapse after induction of remission (weeks) at ≥ 12 months Tocilizumab weekly vs placebo + 26‐week taper | no estimate extracted | NR | No studies |
Cumulative mean dose of corticosteroids at ≥ 12 months Tocilizumab weekly vs placebo + 26‐week taper | no estimate extracted | NR | No studies |
Proportion of participants who did not need escape therapy (as defined by study investigators) Tocilizumab weekly vs placebo + 26‐week taper | RR 2.96 [1.83, 4.78] | 1 study · 150 participants | Moderate Downgraded: imprecision |
Mean change in quality of life at ≥ 12 months using the 36‐Item Short Form Health Survey physical component score (SF‐36 PCS) Tocilizumab weekly vs placebo + 26‐week taper | MD 3.29 | 1 study · 68 participants | Moderate Downgraded: imprecision |
Mean change in quality of life at ≥ 12 months using the 36‐Item Short Form Health Survey mental component score (SF‐36 MCS) Tocilizumab weekly vs placebo + 26‐week taper | MD 3.22 | 1 study · 68 participants | Moderate Downgraded: imprecision |
Mean change in VAS (higher scores suggest greater disease activity and worse quality of life) at ≥ 12 months Tocilizumab weekly vs placebo + 26‐week taper | no estimate extracted | 1 study · 71 participants | Moderate Downgraded: imprecision |
Adverse events at ≥ 12 months Tocilizumab weekly vs placebo + 26‐week taper | RR 1.02 [0.96, 1.09] | 1 study · 150 participants | Moderate Downgraded: imprecision |
Tocilizumab every other week compared to placebo + 52‐week taper for giant cell arteritis
Population: adults aged over 50 years with giant cell arteritis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Proportion of participants with sustained remission (as defined by study investigators) at ≥ 12 months Tocilizumab every other week vs placebo + 52‐week taper | RR 3.01 [1.57, 5.75] | 1 study · 100 participants | Moderate Downgraded: imprecision |
Proportion of participants with relapse‐free survival at ≥ 12 months Tocilizumab every other week vs placebo + 52‐week taper | RR 1.48 [1.08, 2.03] | 1 study · 100 participants | Moderate Downgraded: imprecision |
Proportion of all‐cause mortality at ≥ 12 months Tocilizumab every other week vs placebo + 52‐week taper | no estimate extracted | NR | No studies |
Mean time to first relapse after induction of remission (weeks) at ≥ 12 months Tocilizumab every other week vs placebo + 52‐week taper | no estimate extracted | NR | No studies |
Cumulative mean dose of corticosteroids at ≥ 12 months Tocilizumab every other week vs placebo + 52‐week taper | no estimate extracted | NR | No studies |
Proportion of participants who did not need escape therapy (as defined by study investigators) Tocilizumab every other week vs placebo + 52‐week taper | RR 1.49 [1.04, 2.14] | 1 study · 100 participants | Moderate Downgraded: imprecision |
Mean change in quality of life at ≥ 12 months using the 36‐Item Short Form Health Survey physical component score (SF‐36 PCS) Tocilizumab every other week vs placebo + 52‐week taper | MD 5.51 [0.82, 10.2] | 1 study · 44 participants | Moderate Downgraded: imprecision |
Mean change in quality of life at ≥ 12 months using the 36‐Item Short Form Health Survey mental component score (SF‐36 MCS) Tocilizumab every other week vs placebo + 52‐week taper | no estimate extracted | 1 study · 44 participants | Moderate Downgraded: imprecision |
Mean change in VAS (higher scores suggest greater disease activity and worse quality of life) at ≥ 12 months Tocilizumab every other week vs placebo + 52‐week taper | no estimate extracted | 1 study · 44 participants | Moderate Downgraded: imprecision |
Adverse events at ≥ 12 months Tocilizumab every other week vs placebo + 52‐week taper | RR 1.04 [0.94, 1.15] | 1 study · 100 participants | Moderate Downgraded: imprecision |
Tocilizumab every other week compared to placebo + 26‐week taper for giant cell arteritis
Population: adults aged over 50 years with giant cell arteritis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Proportion of participants with sustained remission (as defined by study investigators) at ≥ 12 months Tocilizumab every other week vs placebo + 26‐week taper | RR 3.79 [1.82, 7.91] | 1 study · 99 participants | Moderate Downgraded: imprecision |
Proportion of participants with relapse‐free survival at ≥ 12 months Tocilizumab every other week vs placebo + 26‐week taper | RR 2.36 [1.53, 3.64] | 1 study · 99 participants | Moderate Downgraded: imprecision |
Proportion of all‐cause mortality at ≥ 12 months Tocilizumab every other week vs placebo + 26‐week taper | no estimate extracted | NR | No studies |
Mean time to first relapse after induction of remission (weeks) at ≥ 12 months Tocilizumab every other week vs placebo + 26‐week taper | no estimate extracted | NR | No studies |
Cumulative mean dose of corticosteroids at ≥ 12 months Tocilizumab every other week vs placebo + 26‐week taper | no estimate extracted | NR | No studies |
Proportion of participants who did not need escape therapy (as defined by study investigators) Tocilizumab every other week vs placebo + 26‐week taper | RR 0.65 [0.27, 1.54] | 1 study · 99 participants | Moderate Downgraded: imprecision |
Mean change in quality of life at ≥ 12 months using the 36‐Item Short Form Health Survey physical component score (SF‐36 PCS) Tocilizumab every other week vs placebo + 26‐week taper | MD 0.63 | 1 study · 35 participants | Moderate Downgraded: imprecision |
Mean change in quality of life at ≥ 12 months using the 36‐Item Short Form Health Survey mental component score (SF‐36 MCS) Tocilizumab every other week vs placebo + 26‐week taper | no estimate extracted | 1 study · 35 participants | Moderate Downgraded: imprecision |
Mean change in VAS (higher scores suggest greater disease activity and worse quality of life) at ≥ 12 months Tocilizumab every other week vs placebo + 26‐week taper | no estimate extracted | 1 study · 37 participants | Moderate Downgraded: imprecision |
Adverse events at ≥ 12 months Tocilizumab every other week vs placebo + 26‐week taper | RR 1 [0.92, 1.08] | 1 study · 99 participants | Moderate Downgraded: imprecision |